Private Danish iron deficiency biotech to buy G1 Therapeutics for $405M

Dozens of pathologists who were told they failed their specialty’s board exam over the past 2 years have been alerted that they actually passed. On

Af­ter re­leas­ing the first-ever re­sults of an in vi­vo base edit­ing ther­a­py in hu­mans, Verve Ther­a­peu­tics has priced a pub­lic of­fer­ing of 12.5 mil­lion shares